Pfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per share in cash. An additional $22.50 per share will be paid if Metsera meets certain performance goals. The announcement is expected soon. This acquisition will strengthen Pfizer's position in the obesity drug market.